Elbit Imaging Ltd. (EMITF) that its subsidiary, InSightec Ltd., announced that Japan's Ministry of Health, Labor and Welfare or MHLW has approved the company's ExAblate MR-guided Focused Ultrasound or MRgFUS system for the treatment of women with uterine fibroids.
ExAblate is currently the only noninvasive treatment for uterine fibroids approved for use in Japan.
InSightec Ltd. estimates that about 25% of Japanese women will develop symptomatic uterine fibroids, primarily during childbearing years. These benign tumors can significantly impair functionality and degrade quality of life, resulting in significant work absences.
For comments and feedback: editorial@rttnews.com